Replies to post #2965 on Navidea Biopharmaceuticals Inc (NAVB)

[sts66]

NAVB managment says they are expecting a class II response.

They said nothing of the sort, and won't until they resubmit the NDA and the FDA tells them. And given the over-worked/under-staffed FDA inspection dept., it may very well be a Class II. See the latest PR:

http://phx.corporate-ir.net/phoenix.zhtml?c=68527&p=irol-nda